Skip to content

Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer

Counseling Intervention During Radiation Therapy for Women With Gynecologic Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04269837
Enrollment
4
Registered
2020-02-17
Start date
2021-05-20
Completion date
2023-04-06
Last updated
2024-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Female Reproductive System Neoplasm, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA Uterine Corpus Cancer AJCC v8, Stage IA Vaginal Cancer AJCC v8, Stage IA Vulvar Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB Uterine Corpus Cancer AJCC v8, Stage IB Vaginal Cancer AJCC v8, Stage IB Vulvar Cancer AJCC v8, Stage I Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Vaginal Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Vaginal Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage II Uterine Corpus Cancer AJCC v8, Stage II Vaginal Cancer AJCC v8, Stage II Vulvar Cancer AJCC v8, Stage I Uterine Corpus Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage I Vaginal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage I Vulvar Cancer AJCC v8

Brief summary

This phase I trial studies a sexual health counseling intervention during radiation therapy in improving quality of life for women with gynecologic cancer. Women with gynecologic cancer often suffer long-term complications from treatment that can affect their physical and psychological well-being. An early sexual health counseling intervention prior to and after radiation may improve symptoms management and reduce the physical and psychological effects of treatment.

Detailed description

PRIMARY OBJECTIVE: I. To determine the feasibility of a sexual health counseling intervention before and after pelvic radiation for women with gynecologic cancers. SECONDARY OBJECTIVE: I. To preliminarily evaluate the efficacy of a sexual health counseling intervention on patient reported outcomes in quality of life, sexual function, and genitourinary symptoms. OUTLINE: Patients receive sexual health counseling prior to starting and at the completion of radiation. After completion of study, patients are followed up at 1 and 6 months after radiation.

Interventions

OTHERCounseling

Receive sexual health counseling

OTHERQuality-of-Life Assessment

Ancillary studies

OTHERQuestionnaire Administration

Ancillary studies

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any patient with endometrial, cervical, vaginal, or vulvar cancer receiving adjuvant external beam radiation or definitive external beam radiation and brachytherapy will be eligible for the study * Those receiving concurrent chemotherapy will be eligible * Any prior gynecologic surgery is permitted

Exclusion criteria

* Patients with metastatic or recurrent disease and patients receiving brachytherapy alone

Design outcomes

Primary

MeasureTime frameDescription
Overall completionUp to 6 months post radiationPatients' characteristics and responses to the questionnaires will be summarized using appropriate summary statistics based on their distributions. Parametric tests such as the student's t test and Chi-square test or nonparametric tests such as Mann-Whitney U test and Fisher's exact test will be used to compare patients' characteristics between patients who completed the program and those who did not.
Individual completion of the counseling sessions and questionnairesUp to 6 months post radiationPatients' characteristics and responses to the questionnaires will be summarized using appropriate summary statistics based on their distributions. Parametric tests such as the student's t test and Chi-square test or nonparametric tests such as Mann-Whitney U test and Fisher's exact test will be used to compare patients' characteristics between patients who completed the program and those who did not.

Secondary

MeasureTime frameDescription
Quality of life (QoL)Up to 6 months post radiationWill be assesses using the European Organization for Research and Treatment of Cancer (EORTC) Core QoL Questionnaire (EORTC QLQ-C30). Data will be displayed graphically using boxplots, histograms and scatterplots to identify interesting features and potential outliers.
Sexual functionUp to 6 months post radiationWill be assessed using the EORTC QLQ-CX24. Data will be displayed graphically using boxplots, histograms and scatterplots to identify interesting features and potential outliers.
Genitourinary symptoms using Vaginal Heal Assessment (VHA)Up to 6 months post radiationWill be assessed using the VHA. Data will be displayed graphically using boxplots, histograms and scatterplots to identify interesting features and potential outliers.The Vaginal Health Assessment, the examination tool used in the clinical validation of the VAS, will be utilized to for the gynecologic physical examination for all patients. 15 The assessment evaluates the physical aspect of the vagina including agglutination, adhesions, pH, dryness, rugosity, elasticity, length, thickness, epithelial integrity, vascularity, and irritation. Vaginal diameter will also be assessed during the manual portion of the exam. Estimates will be \<2.5, 2.5, 3.0, 3.5, 4.0 or \>4 cm. 16
Genitourinary symptoms using Vaginal Assessment Scale (VAS)Up to 6 months post radiationWill be assessed using the VAS. Data will be displayed graphically using boxplots, histograms and scatterplots to identify interesting features and potential outliers. Each item is scored from 0 (none) to 3 (severe) and a composite score is calculated by taking the mean of the items. A lower score indicates better function. In cancer patients and survivors, the scale were found to have high internal consistency.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026